keyword
MENU ▼
Read by QxMD icon Read
search

Certolizumab pegol

keyword
https://www.readbyqxmd.com/read/29335342/comparative-efficacy-of-tumor-necrosis-factor-%C3%AE-inhibitors-in-ankylosing-spondylitis-a-systematic-review-and-bayesian-network-metaanalysis
#1
Runsheng Wang, Abhijit Dasgupta, Michael M Ward
OBJECTIVE: To compare the efficacy of 6 tumor necrosis factor-α inhibitors (TNFi) in treatment of ankylosing spondylitis (AS) at 12 weeks and 24 weeks. METHODS: We performed a systematic literature review of randomized controlled trials of TNFi in patients with active AS. We included trials that reported efficacy at 10 to 14 weeks (12-week analysis) and at 24 to 30 weeks (24-week analysis). We used Bayesian network metaanalysis (NMA) to compare their relative efficacy to improve the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and C-reactive protein (CRP) level...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29329557/one-year-risk-of-serious-infection-in-patients-treated-with-certolizumab-pegol-as-compared-with-other-tnf-inhibitors-in-a-real-world-setting-data-from-a-national-u-s-rheumatoid-arthritis-registry
#2
Leslie R Harrold, Heather J Litman, Katherine C Saunders, Kimberly J Dandreo, Bernice Gershenson, Jeffrey D Greenberg, Robert Low, Jeffrey Stark, Robert Suruki, Srihari Jaganathan, Joel M Kremer, Mohamed Yassine
BACKGROUND: Registry studies provide a valuable source of comparative safety data for tumor necrosis factor inhibitors (TNFi) used in rheumatoid arthritis (RA), but they are subject to channeling bias. Comparing safety outcomes without accounting for channeling bias can lead to inaccurate comparisons between TNFi prescribed at different stages of the disease. In the present study, we examined the incidence of serious infection and other adverse events during certolizumab pegol (CZP) use vs other TNFi in a U...
January 2, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29321825/umbilical-cord-blood-stem-cell-treatment-for-a-patient-with-psoriatic-arthritis
#3
Margaret Coutts, Rowena Soriano, Rajendran Naidoo, Habib Torfi
Clinical and laboratory results document psoriatic arthritis in a 56-year old patient. The symptoms did not resolve with standard treatments (nonsteroidal anti-inflammatory drugs, steroids and methotrexate). TNF-alpha inhibitors (certolizumab pegol and adalimumab) were added to the treatment regime, with some adverse effects. A trial of human umbilical cord stem cell therapy was then initiated. The stem cells were enriched and concentrated from whole cord blood, by removal of erythrocytes and centrifugation...
December 26, 2017: World Journal of Stem Cells
https://www.readbyqxmd.com/read/29294598/rapid-onset-of-efficacy-predicts-response-to-therapy-with-certolizumab-plus-methotrexate-in-patients-with-active-rheumatoid-arthritis
#4
Young Mo Kang, Young-Eun Park, Won Park, Jung-Yoon Choe, Chul-Soo Cho, Seung-Cheol Shim, Sang Cheol Bae, Chang-Hee Suh, Hoon-Suk Cha, Eun Mi Koh, Yeong-Wook Song, Bin Yoo, Shin-Seok Lee, Min-Chan Park, Sang-Heon Lee, Catherine Arendt, Willem Koetse, Soo-Kon Lee
Background/Aims: The objective of this study was to determine the efficacy and safety of add-on therapy with certolizumab pegol (CZP) in active rheumatoid arthritis (RA) patients of a single ethnicity. Methods: In this 24-week, phase 3, randomized, double-blind, placebo-controlled trial, eligible patients (n = 127) were randomized 2:1 to subcutaneous CZP + methotrexate (MTX; 400 mg at week 0, 2, and 4 followed by 200 mg every 2 weeks) or placebo + MTX. Results: At week 24, the American College of Rheumatology criteria for 20% (ACR20) response rate was significantly greater with CZP + MTX than with placebo (66...
January 5, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29278210/biologics-in-inflammatory-and-immunomediated-arthritis
#5
Michele Maria Luchetti, Devis Benfaremo, Armando Gabrielli
BACKGROUND: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis. METHODS: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases...
December 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29246162/use-of-a-baseline-risk-score-to-identify-the-risk-of-serious-infectious-events-in-patients-with-rheumatoid-arthritis-during-certolizumab-pegol-treatment
#6
Jeffrey R Curtis, Kevin Winthrop, Cathy O'Brien, Matladi N Ndlovu, Marc de Longueville, Boulos Haraoui
BACKGROUND: The risk of serious infectious events (SIEs) is increased in patients with rheumatoid arthritis (RA). The aim of this study was to develop an age-adjusted comorbidity index (AACI) to predict, using baseline characteristics, the SIE risk in patients with RA treated with certolizumab pegol (CZP). METHODS: Data of CZP-treated patients with RA were pooled from the RAPID1/RAPID2 randomized controlled trials (RCT CZP) and their open-label extensions (All CZP)...
December 15, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29232326/certolizumab-pegol-induced-heart-failure
#7
Karina Lazarewicz, Steven Shaw, Sahena Haque
No abstract text is available yet for this article.
December 12, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29222625/using-patient-feedback-to-optimize-the-design-of-a-certolizumab-pegol-electromechanical-self-injection-device-insights-from-human-factors-studies
#8
Barbara Domańska, Oliver Stumpp, Steven Poon, Serkan Oray, Irina Mountian, Clovis Pichon
INTRODUCTION: We incorporated patient feedback from human factors studies (HFS) in the patient-centric design and validation of ava®, an electromechanical device (e-Device) for self-injecting the anti-tumor necrosis factor certolizumab pegol (CZP). METHODS: Healthcare professionals, caregivers, healthy volunteers, and patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or Crohn's disease participated in 11 formative HFS to optimize the e-Device design through intended user feedback; nine studies involved simulated injections...
December 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29177802/correction-to-certolizumab-pegol-in-the-treatment-of-psoriasis-and-psoriatic-arthritis-preliminary-real-life-data
#9
Annunziata Dattola, Maria Vittoria Cannizzaro, Mauro Mazzeo, Luca Bianchi
In the original publication, part Fig. 3b and c were interchanged. The correct versions are given below.
November 25, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29159893/exposure-response-relationship-of-certolizumab-pegol-induction-and-maintenance-therapy-in-patients-with-crohn-s-disease
#10
N Vande Casteele, B G Feagan, S Vermeire, M Yassine, J Coarse, G Kosutic, W J Sandborn
BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM: To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-response relationship for CZP in Crohn's disease. METHODS: Adults (N = 2157) with Crohn's disease were treated with CZP in nine clinical trials. Simulated CZP concentrations were compared to outcomes at weeks 6 and 26, including Crohn's disease activity index (CDAI) response (decrease from baseline ≥ 100 points), remission (CDAI ≤ 150), C-reactive protein (CRP) ≤ 5 mg/L, faecal calprotectin (FC) ≤ 250 μg/g, and a composite endpoint of CDAI ≤ 150 and FC ≤ 250 μg/g...
November 21, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29141665/matrix-metalloproteinase-3-and-the-7-joint-ultrasound-score-in-the-assessment-of-disease-activity-and-therapeutic-efficacy-in-patients-with-moderate-to-severe-rheumatoid-arthritis
#11
Ling Zhou, Geng Wang, Xin Liu, Jing Song, Ling Chen, Huji Xu
BACKGROUND: This study aimed to investigate the reliability and validity of serum matrix metalloproteinase-3 (MMP-3) levels and articular ultrasound (US) scores in assessing disease activity and therapeutic response in rheumatoid arthritis (RA) patients. METHODS: A total of 151 RA patients were enrolled, of whom 22 were treated with certolizumab pegol (Cimzia, CZP). The RA patients were divided into the following four subgroups according to their disease activity score in 28 joints (DAS28): stable, mild activity, moderate activity, and high activity...
November 15, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29139035/certolizumab-pegol-in-the-treatment-of-psoriasis-and-psoriatic-arthritis-preliminary-real-life-data
#12
Annunziata Dattola, Maria Vittoria Cannizzaro, Mauro Mazzeo, Luca Bianchi
INTRODUCTION: We present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthritis and PsA. METHODS: Assessments included an evaluation of the Psoriasis Area and Severity Index (PASI) and the Disease Activity Score computed on 44 joints (DAS-44) correlated to the erythrocyte sedimentation rate (ESR) (DAS44-ESR)...
December 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#13
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
December 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29039054/treatment-persistence-and-healthcare-costs-among-patients-with-rheumatoid-arthritis-changing-biologics-in-the-usa
#14
Benjamin Chastek, Chieh-I Chen, Clare Proudfoot, Shraddha Shinde, Andreas Kuznik, Wenhui Wei
INTRODUCTION: After a patient with rheumatoid arthritis (RA) fails tumor necrosis factor inhibitor (TNFi) treatment, clinical guidelines support either cycling to another TNFi or switching to a different mechanism of action (MOA), but payers often require TNFi cycling before they reimburse switching MOA. This study examined treatment persistence, cost, and cost per persistent patient among MOA switchers versus TNFi cyclers. METHODS: This study of Commercial and Medicare Advantage claims data from the Optum Research Database included patients with RA and at least one claim for a TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) between January 2012 and September 2015 who changed to another TNFi or a different MOA therapy (abatacept, tocilizumab, or tofacitinib) within 1 year...
October 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29033821/certolizumab-pegol-induced-folliculitis-like-lichenoid-sarcoidosis-in-a-patient-with-rheumatoid-arthritis
#15
Hiroyuki Sakai, Wakana Nomura, Motoshi Sugawara
Anti-tumor necrosis factor α (TNF-α) biologic agents are used for treating refractory sarcoidosis. However, sarcoidosis-like epithelioid cell granulomas may develop during anti-TNF-α treatment. A 63-year-old man suffering from rheumatoid arthritis was treated with oral methotrexate and methylprednisolone for 4 years. He subsequently started biweekly subcutaneous injections of certolizumab pegol. Three months later, light red follicular papules developed on his chest and they spread over the trunk and bilateral upper arms...
September 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29030361/lack-of-placental-transfer-of-certolizumab-pegol-during-pregnancy-results-from-crib-a-prospective-postmarketing-pharmacokinetic-study
#16
Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D Flynn, Anna Moltó, René-Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Wang, Eliza F Chakravarty
OBJECTIVES: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases. This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregnant women to their infants. METHODS: CRIB was a pharmacokinetic (PK) study of women ≥30 weeks pregnant receiving commercial CZP for a locally approved indication (last dose ≤35 days prior to delivery). Blood samples were collected from mothers, umbilical cords and infants at delivery, and infants again at weeks 4 and 8 post-delivery...
October 13, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29026838/tumor-necrosis-factor-alpha-antibodies-in-fistulizing-crohn-s-disease-an-updated-systematic-review-and-meta-analysis
#17
REVIEW
Pardis Zaboli, Mohammad Abdollahi, Shilan Mozaffari, Shekoufeh Nikfar
Medical treatment for fistulizing Crohn's disease (FCD) is changing rapidly over the time by the introduction of novel therapeutic medicines, while no global consensus is available. This study aims to accomplish a systematic review and meta-analysis on the efficacy of tumor necrosis factor-alpha antibodies (anti-TNF-α antibodies) versus placebo in FCD. A systematic review of published literature was carried out till December 2016, and a meta-analysis of identified studies was done. Data have been explored from PubMed, Scopus, Cochrane Library Database, and Web of Science...
July 2017: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/28976302/certolizumab-pegol-and-secukinumab-for-treating-active-psoriatic-arthritis-following-inadequate-response-to-disease-modifying-antirheumatic-drugs-a-systematic-review-and-economic-evaluation
#18
Mark Corbett, Fadi Chehadah, Mousumi Biswas, Thirimon Moe-Byrne, Stephen Palmer, Marta Soares, Matthew Walton, Melissa Harden, Pauline Ho, Nerys Woolacott, Laura Bojke
BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA®, Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC; COSENTYX®, Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA®, UCB Pharma, Brussels, Belgium) have not previously been appraised by NICE...
October 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28975568/modeled-health-economic-impact-of-a-hypothetical-certolizumab-pegol-risk-sharing-scheme-for-patients-with-moderate-to-severe-rheumatoid-arthritis-in-finland
#19
Erkki Soini, Christian Asseburg, Maarit Taiha, Kari Puolakka, Oana Purcaru, Riitta Luosujärvi
PURPOSE: To model the American College of Rheumatology (ACR) outcomes, cost-effectiveness, and budget impact of certolizumab pegol (CZP) (with and without a hypothetical risk-sharing scheme at treatment initiation for biologic-naïve patients) versus the current mix of reimbursed biologics for treatment of moderate-to-severe rheumatoid arthritis (RA) in Finland. METHODS: A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015-2019, accounting for differences in ACR responses (meta-analysis), mortality, and persistence...
October 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28975392/second-line-treatment-persistence-and-costs-among-patients-with-immune-mediated-rheumatic-diseases-treated-with-subcutaneous-tnf-alpha-inhibitors
#20
Johan Dalén, Axel Svedbom, Christopher M Black, Sumesh Kachroo
The objective of this study was to describe treatment persistence with second-line subcutaneous tumor necrosis factor-alpha inhibitors (SC-TNFis) in patients with immune-mediated rheumatic diseases (IMRDs) in Sweden, and the impact of non-persistence on healthcare costs. This retrospective observational study was based on Swedish national health register data. Adults were identified through filled prescriptions for adalimumab (ADA), etanercept (ETA), certolizumab pegol (CZP) and golimumab (GLM). Persistence was estimated over 3 years for propensity score-matched (PSM) cohorts using non-parametric survival analysis...
December 2017: Rheumatology International
keyword
keyword
65664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"